Clinicopathologic and11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum
Open accessThe DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.
Abstract
Thal amyloid phase, which describes the pattern of progressive amyloid-β plaque deposition in Alzheimer's disease, was incorporated into the latest National Institute of Ageing - Alzheimer's Association neuropathologic assessment guidelines. Amyloid biomarkers (positron emission tomography and cerebrospinal fluid) were included in clinical diagnostic guidelines for Alzheimer's disease dementia published by the National Institute of Ageing - Alzheimer's Association and the International Work group. Our first goal was to evaluate the correspondence of Thal amyloid phase to Braak tangle stage and ante-mortem clinical characteristics in a large autopsy cohort. Second, we examined the relevance of Thal amyloid phase in a prospectively-followed autopsied cohort who underwent ante-mortem (11)C-Pittsburgh compound B imaging; using the large autopsy cohort to broaden our perspective of (11)C-Pittsburgh compound B results. The Mayo Clinic Jacksonville Brain Bank case series (n = 3618) was selected regardless of ante-mortem clinical diagnosis and neuropathologic co-morbidities, and all assigned Thal amyloid phase and Braak tangle stage using thioflavin-S fluorescent microscopy. (11)C-Pittsburgh compound B studies from Mayo Clinic Rochester were available for 35 participants scanned within 2 years of death. Cortical (11)C-Pittsburgh compound B values were calculated as a standard uptake value ratio normalized to cerebellum grey/white matter. In the high likelihood Alzheimer's disease brain bank cohort (n = 1375), cases with lower Thal amyloid phases were older at death, had a lower Braak tangle stage, and were less frequently APOE-ε4 positive. Regression modelling in these Alzheimer's disease cases, showed that Braak tangle stage, but not Thal amyloid phase predicted age at onset, disease duration, and final Mini-Mental State Examination score. In contrast, Thal amyloid phase, but not Braak tangle stage or cerebral amyloid angiopathy predicted (11)C-Pittsburgh compound B standard uptake value ratio. In the 35 cases with ante-mortem amyloid imaging, a transition between Thal amyloid phases 1 to 2 seemed to correspond to (11)C-Pittsburgh compound B standard uptake value ratio of 1.4, which when using our pipeline is the cut-off point for detection of clear amyloid-positivity regardless of clinical diagnosis. Alzheimer's disease cases who were older and were APOE-ε4 negative tended to have lower amyloid phases. Although Thal amyloid phase predicted clinical characteristics of Alzheimer's disease patients, the pre-mortem clinical status was driven by Braak tangle stage. Thal amyloid phase correlated best with (11)C-Pittsburgh compound B values, but not Braak tangle stage or cerebral amyloid angiopathy. The (11)C-Pittsburgh compound B cut-off point value of 1.4 was approximately equivalent to a Thal amyloid phase of 1-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For amyloid imaging, where over a decade of data are available, different ligands, methods of image acquisition, and image processing can result in different thresholds when compared to neuropathologic standards [21,22,196].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies suggest that NFT pathology closely correlates with neurodegeneration and cognitive decline [1, 2].”
From Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“supports recent evidence that tau may play an early pathological role in Alzheimer’s disease129–131”
From Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“Imaging-to-autopsy comparison studies have established that amyloid positron emission tomography (PET) is a valid in vivo surrogate for Aβ deposits (in brain parenchyma/vessel walls) [17–24].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“A typical cut point used for 11C Pittsburgh compound B approximately labels individuals with Thal phase 0–1 normal and individuals with Thal phase 2–5 abnormal [21].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · cited 1×
“Ante-mortem clinical history for age at onset of cognitive symptoms, education, and Mini-Mental State Examination (MMSE) score (Folstein et al., 1975) was retrospectively abstracted from clinical reports for the Mayo Clinic Jacksonville series, with investigators blinded to Thal amyloid phase.”
MethodHirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 4×
“CSF) have been included in NIA-AA clinical diagnostic guidelines for Alzheimer’s disease dementia (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011).”
BackgroundMethodInfluentialSelf-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 7×
“A Braak NFT stage of 5IV is consistent with NFTs restricted to limbic regions and not yet involving cortical regions (Braak and Braak, 1991).”
BackgroundMethodInfluentialAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 2×
“CSF) have been included in NIA-AA clinical diagnostic guidelines for Alzheimer’s disease dementia (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011).”
MethodSelf-citationSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 2×
“well as preclinical stages of the disease (Jack et al., 2011; McKhann et al., 2011; Sperling et al., 2011).”
BackgroundMethodSelf-citation
Research works printed but not linked: 1
- 10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x · doi:10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x
Cited by
Items 201–300 of 351
Association of PET‐based stages of amyloid deposition with neuropathological markers of Aβ pathology
Teipel, S. J., Temp, A. G. M., Levin, F., Dyrba, M., Grothe, M. J., & Initiative, A. D. N. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51238 · Cited by 19
“Our findings support a previous study of 35 cases where a global cut-off for 11C-PIB-PET positivity was associated with the binary distinction between low to moderate (0– 2) versus high (3–5) Thal phases.(36) In addition, one previous clinico-pathological comparison study in a subsample of the data from 9 likewise rep…”
ResultThe Dichotomy of Alzheimer’s Disease Pathology: Amyloid-β and Tau
Ashford, J. W. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181198 · Cited by 19
Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer’s and Parkinson’s Diseases
Hessen, E., Stav, A. L., Auning, E., Selnes, P., Blomsø, L., Holmeide, C. E., Johansen, K. K., Eliassen, C. F., Reinvang, I., Fladby, T., et al. (2016) · Journal of Parkinson s Disease · doi:10.3233/jpd-150761 · Cited by 19
“Keywords: Mild cognitive impairment, Parkinson’s disease, Alzheimer’s disease, neuropsychology, cerebrospinal fluid biomarkers”
BackgroundMa, D., Luo, Y., Huang, R., Zhao, Z., Wang, Q., Li, L., & Zhang, L. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200103113158 · Cited by 19
Shigemoto, Y., Sone, D., Imabayashi, E., Maikusa, N., Okamura, N., Furumoto, S., Kudo, Y., Ogawa, M., Takano, H., Yokoi, Y., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00223 · Cited by 18
Josephs, K. A., Zhang, Y., Baker, M., Rademakers, R., Petrucelli, L., & Dickson, D. W. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0755-x · Cited by 18
Self-citationA New Use for an Old Treatment: Radiation Therapy and Alzheimer's Disease
Wilson, G. D., & Marples, B. (2016) · Radiation Research · doi:10.1667/rr14367.1 · Cited by 18
Hayashi, H., Kobayashi, R., Kawakatsu, S., Morioka, D., & Otani, K. (2020) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000507654 · Cited by 18
Neergaard, J. S., Dragsbæk, K., Christiansen, C., Karsdal, M. A., Brix, S., & Henriksen, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194802 · Cited by 17
Cognitive deficits in human ApoE4 knock-in mice: A systematic review and meta-analysis
van Heuvelen, M. J. G., van der Lei, M. B., Alferink, P. M., Roemers, P., & van der Zee, E. A. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115123 · Cited by 16
“It remains unclear which processes cause AD or to what extent ApoE exerts interactive or independent effects explaining the risks of the ApoE4 allele [23,26,61,87].”
BackgroundZilioli, A., Pancaldi, B., Baumeister, H., Busi, G., Misirocchi, F., Mutti, C., Florindo, I., Morelli, N., Mohanty, R., Berron, D., et al. (2024) · Brain Imaging and Behavior · doi:10.1007/s11682-024-00952-0 · Cited by 16
“Over the years, it has been consistently shown that the impact of amyloid pathology on neurodegeneration and subsequent atrophy of the medial-temporal regions is not direct but could be considered primarily mediated by tau pathology (Murray et al., 2015; Jagust, 2016).”
Buck, S. A., Malankhanova, T. B., Strader, S., Eileen, B., Yim, S., Pratt, H. W., Ervin, J. F., Lee, E. B., Wang, S. J., Cohen, T. J., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02951-x · Cited by 16
“Severity of amyloid-β pathology was not quantified, although amyloid-β PET imaging shows strong correlation of amyloid-β plaque load with Thal amyloid phase, with elevated amyloid-β plaque load in hippocampal regions found at later Thal amyloid phases [85].”
Neuroimaging of Diseases Causing Dementia
Masdeu, J. C. (2019) · Neurologic Clinics · doi:10.1016/j.ncl.2019.08.003 · Cited by 16
Antemortem Prediction of Braak Stage
Carlson, J. O. E., Gatz, M., Pedersen, N. L., Graff, C., Nennesmo, I., Lindström, A.-K., & Gerritsen, L. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000251 · Cited by 16
“Braak staging is a validated neuropathologic method to assess the spread of cortical NFT (38), and meta-analyses of autopsy studies also reveal that it currently is the most significant neuropathologic correlate of dementia (6, 32, 33).”
BackgroundMethodKhalafi, M., Hojjati, S. H., Wang, X. H., Zhou, L., Nordvig, A. S., Li, Y., Butler, T., Razlighi, Q. R., Tanzi, E. B., Pahlajani, S. S., et al. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8743 · Cited by 15
MCI Criteria in ADNI: Meeting Biological Expectations
Petersen, R. C. (2021) · Neurology · doi:10.1212/wnl.0000000000012588 · Cited by 15
“Unpublished data from the ADNI NeuropathologyCore demonstrate that, of 39 persons diagnosed with LMCI at enrollment in the study who subsequently went on to have an autopsy, 31 hadThal Stages IV or V, and another 3 had Thal Stage III, suggesting that the ADNI MCI criteria do, in fact, predict progression and the prese…”
MethodSelf-citationHayashi, H., Kobayashi, R., Kawakatsu, S., Ohba, M., Morioka, D., & Otani, K. (2021) · Psychogeriatrics · doi:10.1111/psyg.12729 · Cited by 15
Preventing the Spread of Alzheimer’s Disease Neuropathology: A Role for Calcilytics?
Chiarini, A., Gardenal, E., Whitfield, J., Chakravarthy, B., Armato, U., & Prà, I. D. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201016666150505123813 · Cited by 14
Hua, J., Lee, S. W., Blair, N. I. S., Wyss, M., Bergen, J. M. G. V., Schreiner, S. J., Kagerer, S. M., Leh, S. E., Gietl, A. F., Treyer, V., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.01.001 · Cited by 14
“Consistently, brain regions with significant correlations between CBVa and Ab in our study included the neocortex and hippocampal formation, which are considered particularly susceptible for AD pathology (Murray et al., 2015).”
Kell, D., & Pretorius, E. (2016) · bioRxiv · doi:10.1101/054734 · Cited by 21
The Concept of an Epilepsy Brain Bank
Hernández‐Ronquillo, L., Mahabadi, H. M., Moien‐Afshari, F., Wu, A., Auer, R. N., Zherebitskiy, V. A., Borowsky, R., Mickleborough, M., Huntsman, R. J., Vrbancic, M. I., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00833 · Cited by 13
“Why Is It Important to Develop Epilepsy Brain Banks in Canada and Elsewhere Around the World? The discovery of the molecular underpinnings and potential treatments of human epilepsy based on new molecular targets is demonstrably lagging behind progress made in neurodegenerative diseases such as AD and PD (14), partly…”
BackgroundCarvalho, D. Z., Křemen, V., Mívalt, F., Louis, E. K. S., McCarter, S. J., Bukartyk, J., Przybelski, S. A., Kamykowski, M. G., Spychalla, A. J., Machulda, M. M., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae354 · Cited by 13
“51 Our primary outcome measure was annualized global PiB accumulation, hereafter referred to as global Δ PiB SUVR(log)/year.”
BackgroundSelf-citationBoon, B. D. C., Labuzan, S. A., Peng, Z., Matchett, B. J., Kouri, N., Hinkle, K. M., Lachner, C., Ross, O. A., Ertekin‐Taner, N., Carter, R. E., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207685 · Cited by 13
“Aβ topographic distribution remains relatively consistent across autopsied AD cases.(3)”
BackgroundMethodSelf-citationJosephs, K. A., Koga, S., Tosakulwong, N., Weigand, S. D., Pham, N. T. T., Baker, M. C., Whitwell, J. L., Rademakers, R., Petrucelli, L., & Dickson, D. W. (2023) · Free Neuropathology · doi:10.17879/freeneuropathology-2023-5192 · Cited by 13
Self-citationValentino, R. R., Tamvaka, N., Heckman, M. G., Johnson, P. W., Soto‐Beasley, A. I., Walton, R. L., Koga, S., Uitti, R. J., Wszołek, Z. K., Dickson, D. W., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01035-z · Cited by 13
Self-citationTau Positron Emission Tomography Imaging in Degenerative Parkinsonisms
Lyoo, C. H., Cho, H., Choi, J. Y., Ryu, Y. H., & Lee, M. S. (2018) · Journal of Movement Disorders · doi:10.14802/jmd.17071 · Cited by 13
Generative AI unlocks PET insights: brain amyloid dynamics and quantification
Bossa, M. N., Nakshathri, A. G., Berenguer, A. D., & Hichem Sahli, B. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1410844 · Cited by 12
Theunis, C., Adolfsson, O., Crespo‐Biel, N., Piorkowska, K., Pihlgren, M., Hickman, D. T., Gafner, V., Borghgraef, P., Devijver, H., Pfeifer, A., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160695 · Cited by 12
“: +41 21 345 91 24; Fax: +41 21 345 91 20; E-mail: andreas.muhs@acimmune.com. about severe personal, social, and economic burden.”
Perani, D., Iaccarino, L., Jacobs, A. H., IMBI Brain Imaging Working Group, Lammertsma, A. A., Nordberg, A. K., Windhorst, A. D., Gerhard, A., Winkeler, A., Jacobs, A. H., et al. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.02.004 · Cited by 13
Satake, Y., Kanemoto, H., Yoshiyama, K., Nakahama, R., Matsunaga, K., Shimosegawa, E., Morihara, T., Hashimoto, M., & Ikeda, M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.742659 · Cited by 12
A novel Aβ epitope vaccine based on bacterium-like particle against Alzheimer’s disease
Fu, L., Guo, Y., Sun, Y., Dong, Y., Wu, J., Yu, B., Zhang, H., Yu, X., Wu, H., & Kong, W. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.07.019 · Cited by 12
Valentino, R. R., Koga, S., Heckman, M. G., Brushaber, D. E., Diehl, N. N., Walton, R. L., Dickson, D. W., & Ross, O. A. (2020) · Movement Disorders · doi:10.1002/mds.28010 · Cited by 12
Self-citationVerfaillie, S. C. J., Golla, S. S. V., Timmers, T., Tuncel, H., van der Weijden, C. W. J., Schober, P. R., Schuit, R. C., van der Flier, W. M., Windhorst, A. D., Lammertsma, A. A., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20915403 · Cited by 12
Genetic influences on cognition in progressive supranuclear palsy
Gerstenecker, A. T., Roberson, E. D., Schellenberg, G. D., Standaert, D. G., Shprecher, D., Kluger, B. M., & Litvan, I. (2017) · Movement Disorders · doi:10.1002/mds.27196 · Cited by 12
Siddiqui, T., Çelikkaya, H., Atasavum, Z. T., Popova, S. D., Freudenberg, U., Werner, C., & Kızıl, Ç. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2655-9_8 · Cited by 11
Bayram, E., Coughlin, D. G., Koga, S., Ross, O. A., Litvan, I., & Dickson, D. W. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70083 · Cited by 11
Self-citationBlazhenets, G., Frings, L., Sörensen, A., & Meyer, P. T. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.252783 · Cited by 11
Subcortical amyloid load is associated with shape and volume in cognitively normal individuals
Rahayel, S., Bocti, C., Sévigny-Dupont, P., Joannette, M., Lavallée, M. M., Nikelski, J., Chertkow, H. M., & Joubert, S. (2019) · Human Brain Mapping · doi:10.1002/hbm.24680 · Cited by 11
“Aβ binding ligands such as 11C-Pittsburgh compound B (PiB) allow for in vivo quantification of Aβ in the brain (Klunk et al., 2004; Murray et al., 2015).”
BackgroundDiaz‐Galvan, P., Przybelski, S. A., Lesnick, T. G., Murray, M. E., Nguyen, A. T., Reichard, R. R., Dickson, D. W., Ono, D., Senjem, M. L., Schwarz, C. G., et al. (2025) · Movement Disorders · doi:10.1002/mds.30265 · Cited by 10
Self-citationImpact of APOE on cerebrovascular lipid profile in Alzheimer’s disease
Inoue, Y., Wang, H., Heckman, M. G., Ren, Y., White, L. J., Lü, W., Wang, P., Julia, T. C. W., Koga, S., Alnobani, A., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02949-5 · Cited by 10
“We assessed AD neuropathologic changes, including Braak tangle stage and Thal amyloid phase, as described previously [7, 46, 62].”
Self-citationClinical–biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data
Trudel, L., Therriault, J., Macedo, A. C., Hosseini, S. A., Arias, J. F., Chan, T., Rahmouni, N., Bezgin, G., Tissot, C., Woo, M. S., et al. (2026) · Brain · doi:10.1093/brain/awag018 · Cited by 10
Devanand, D. P., Lee, S., Luchsinger, J. A., Knopman, D. S., Vassilaki, M. E., & Motter, J. N. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14261 · Cited by 10
Self-citationPathological Human Tau Induces Alterations in the Brain Insulin Signaling Cascade
Idrissi, A. E., & Alonso, A. D. C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.805046 · Cited by 10
Stereological Quantification of Plaques and Tangles in Neocortex from Alzheimer’s Disease Patients
Madsen, J. B., Folke, J., & Pakkenberg, B. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180105 · Cited by 10
Bergeron‐Brlek, M., Goodwin‐Tindall, J., Cekic, N., Roth, C., Zandberg, W. F., Shan, X., Varghese, V., Chan, S., Davies, G. J., Vocadlo, D. J., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201507985 · Cited by 10
Albin, R. L., Fisher‐Hubbard, A., Shanmugasundaram, K., Koeppe, R. A., Burke, J. F., Camelo-Piragua, S. I., Lieberman, A. P., Giordani, B., & Frey, K. A. (2015) · Annals of Neurology · doi:10.1002/ana.24481 · Cited by 9
Clear‐headed into old age: Resilience and resistance against brain aging—A PET imaging perspective
Hoenig, M. C., & Drzezga, A. E. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15598 · Cited by 9
(2023) · doi:10.1021/acschemneuro.3c00007 · Cited by 8
Alzheimer's disease clinical variants show distinct neuroinflammatory profiles with neuropathology
Boon, B. D. C., Frigerio, I., de Gooijer, D., Morrema, T. H. J., Bol, J. G. J. M., Galis, Y., Heymans, M. W., Bank, N. B., Murray, M. E., Amsterdam, N. A. B. C., et al. (2024) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.13009 · Cited by 8
“Contrary to tau, amyloid-β distribution is consistently cortical dominant across variants [12, 13].”
Self-citationCelebrating neuropathology's contributions to Alzheimer's Disease Research Centers
Fischer, D. L., Grinberg, L. T., Ahrendsen, J. T., Beach, T. G., Bieniek, K. F., Castellani, R. J., Chkheidze, R., Cobos, I., Cohen, M. L., Crary, J. F., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70734 · Cited by 8
Self-citationPadilha, N. B., Penteado, F., Salomão, M. C., Lopes, E. F., Bettanin, L., Hartwig, D., Jacob, R. G., & Lenardao, E. J. (2019) · Tetrahedron Letters · doi:10.1016/j.tetlet.2019.05.021 · Cited by 8
The puzzle of preserved cognition in the oldest old
Bugiani, O. (2019) · Neurological Sciences · doi:10.1007/s10072-019-04111-y · Cited by 8
“[35] carried out a semi-quantitative study of cerebral Aβ and p-tau in 1375 elderly subjects and found less amyloid and fewer tangles in those whowere older at the time of death and those whowere less frequently carriers of the ApoEε4 allele.”
BackgroundAmyloid PET scan: Staging beyond reading?
Chételat, G., & Murray, M. E. (2017) · Neurology · doi:10.1212/wnl.0000000000004678 · Cited by 8
Self-citationMoloney, C. M., Rutledge, M. H., Labuzan, S. A., Peng, Z., Tranovich, J. F., Wood, A. C., Rothberg, D. M., Duara, R., Lachner, C., Graff‐Radford, N. R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.02.657435 · Cited by 8
Self-citationCatalytic Synthesis of PEGylated EGCG Conjugates that Disaggregate Alzheimer’s Tau
Eisenberg, D. S., Harran, P. G., Khoury, A. E., & Seidler, P. M. (2021) · Synthesis · doi:10.1055/a-1509-5904 · Cited by 7
Affection of Motor Network Regions by Tau Pathology Across the Alzheimer's Disease Spectrum
Bischof, G. N., Jaeger, E., Giehl, K., Hoenig, M. C., Initiative, A. D. N., Weiss, P. H., & Drzezga, A. E. (2023) · eNeuro · doi:10.1523/eneuro.0242-23.2023 · Cited by 7
“For instance, histopathological studies revealed β -amyloid accumulation in primary motor regions in Thal stage 4 and 5 that preceded subcortical burden of β -amyloid in regions of the hippocampus (Murray et al., 2015).”
BackgroundSubcortical amyloid relates to cortical morphology in cognitively normal individuals
Rahayel, S., Bocti, C., Sévigny-Dupont, P., Joannette, M., Lavallée, M. M., Nikelski, J., Chertkow, H. M., & Joubert, S. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04446-w · Cited by 7
“Aβ accumulates for decades prior to the onset of clinical AD [2, 3].”
BackgroundCrespo-Cuevas, A. M., Elena López-Cancio, M., Cáceres, C. M., González, A., Ispierto, L., Hernández‐Pérez, M., Mataró, M., Planas, A. M., Canento, T., Martín-Aguilar, L., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190949 · Cited by 7
Personalized Healthcare for Dementia
Lee, S., Cho, E., & Kwak, H. (2021) · Healthcare · doi:10.3390/healthcare9020128 · Cited by 7
Pivtoraiko, V. N., Racic, T., Abrahamson, E. E., Villemagne, V. L., Handen, B. L., Lott, I. T., Head, E., & Ikonomović, M. D. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.728739 · Cited by 7
“This approach is consistent with 11C-PiB PET and related amyloid PET radioligands lacking selectivity to distinguish Aβ plaques from CAA (Bacskai et al., 2007; Johnson et al., 2007; Lockhart et al., 2007; Dierksen et al., 2010; Ly et al., 2010; Sabbagh et al., 2011; Ducharme et al., 2013; Murray et al., 2015; Seo et a…”
BackgroundResultMonitoring the progression of Alzheimer’s disease with τ-PET: Table 1
Thal, D. R., & Vandenberghe, R. R. (2016) · Brain · doi:10.1093/brain/aww057 · Cited by 7
Oatman, S. R., Reddy, J. S., Atashgaran, A., Wang, X., Min, Y., Quicksall, Z., Vanelderen, F., Carrasquillo, M. M., Liu, C.-C., Yamazaki, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68864-9 · Cited by 6
“Braak stage, Thal phase, and CAA scores were measured using previously established protocols 3,4,10,146,147 .”
Self-citationXie, H., Li, Y., Wu, X., Wang, R., Long, X., Su, M., Chen, Q., Li, L., Tian, R., & Jia, Z. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-23-268 · Cited by 6
“We also calculated the Δ SUVR values between the G15 and other groups to describe the effects of scanning time on SUVR values (24).”
Clinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies
Franceschi, A. M., Keir, G., Benzinger, T. L. S., Cogswell, P. M., Ali, F., Petrella, J. R., Prescott, J. W., Whitlow, C. T., Zaharchuk, G., Allen, J. W., et al. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8738 · Cited by 6
Lee, D., Park, J., Jung, K. S., Kim, J., Jang, J. S., Kwon, S., Byun, M. S., Yi, D., Byeon, G., Jung, G., et al. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00719-3 · Cited by 6
Petersen, R. C., Graf, A., Brady, C., Santi, S. D., Florian, H., Landen, J. W., Pontecorvo, M., RANDOLPH, C. C., Sink, K. M., Carrillo, M. C., et al. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12434 · Cited by 6
Self-citationIs dominantly inherited Alzheimer disease a clone of sporadic Alzheimer disease?
Knopman, D. S. (2015) · Neurology · doi:10.1212/wnl.0000000000001897 · Cited by 6
Self-citationPeng, Y., Wang, S.-S., Lai, K.-D., Ye, J.-R., He, W.-B., Yan, X., Zhang, Z., Chu, S.-F., & Chen, N. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01709-1 · Cited by 5
Yamakuni, R., Murakami, T., Ukon, N., Kakamu, T., Toda, W., Hattori, K., Sekino, H., Ishii, S., Fukushima, K., Matsuda, H., et al. (2024) · Annals of Nuclear Medicine · doi:10.1007/s12149-024-01955-z · Cited by 5
Assembly of synthetic Aβ miniamyloids on polyol templates
Fischer, S. N., & Geyer, A. (2015) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.11.284 · Cited by 5
Noradrenaline, Astroglia, and Neuroinflammation
Madrigal, J. L. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805088-0.00014-1 · Cited by 5
Franceschi, A. M., Petrover, D. R., Giliberto, L., Clouston, S., & Gordon, M. L. (2022) · World Journal of Nuclear Medicine · doi:10.1055/s-0042-1757290 · Cited by 5
Kobayashi, R., Hayashi, H., Kawakatsu, S., Shibuya, Y., Morioka, D., Ohba, M., Yoshioka, M., Sakamoto, K., Kanoto, M., & Otani, K. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220820145429 · Cited by 5
Data-driven modeling of spatiotemporal dynamics using multimodal imaging data
Li, C., Mao, Y., Liu, X., & Hao, W. (2026) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1014751 · Cited by 4
Deng, J., Wan, W., Sun, R., Xia, Q., Yan, J., Sun, J., Jia, X., Jin, H., Wang, X., Guo, K., et al. (2025) · ACS Sensors · doi:10.1021/acssensors.4c03560 · Cited by 4
Increased Uptake of AV-1451 in a Subacute Infarction Lesion
Cho, S. H., Cho, H., Park, S., Ryu, Y. H., Choi, J. Y., Lyoo, C. H., Na, D. L., Seo, S. W., & Kim, H. J. (2018) · Yonsei Medical Journal · doi:10.3349/ymj.2018.59.4.563 · Cited by 4
Roles of nano medicine in diagnosis of Alzheimer's disease
Kaushal, M. A., Patel, N., Xavier, G., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00017-0 · Cited by 4
Jack, C. R., Knopman, D. S., Wiste, H. J., Sperling, R. A., Jagust, W. J., Murray, M. E., Boon, B. D. C., Lowe, V. J., Johnson, D. R., Burkett, B. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70184 · Cited by 4
Self-citationCui, L., Zhang, Z., Huang, Y., Xie, F., Guan, Y., Lo, C. Z., Guo, Y., Jiang, J., & Guo, Q. (2023) · Brain Imaging and Behavior · doi:10.1007/s11682-023-00780-8 · Cited by 4
“Previous studies have revealed that the sensitivity to Aβ pathology progression in early stages is lower when visual assessment is used to determine PET results (Murray et al., 2015; Dietmar Rudolf Thal, Beach, et al. 2015 ).”
BackgroundInhibition of Tau Aggregation as a Basis for Treatment and Prevention of Alzheimer’s Disease
Wischik, C. M., Storey, J. M. D., Wischik, D., & Harrington, C. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00015-0 · Cited by 4
Leyton, C. E., Cassidy, B., Villemagne, V. L., Jones, G. R., Kwok, J. B., Rowe, C. C., Ballard, K. J., Piguet, O., & Hodges, J. R. (2015) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2015.09.004 · Cited by 3
“Although current imaging techniques of Aβ radiotracers correspond closely with the stereotypical regional progression of Aβ accumulation in postmortem samples (38), these techniques are not yet able to detect molecular subtypes of amyloid.”
BackgroundStimulation of Tau Degradation
Quintanilla, R. A., Cabezas-Opazo, F., Pallo, S. P., Chesser, A. S., & Johnson, G. V. W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00013-7 · Cited by 3
Symptomatic and preclinical Alzheimer’s disease: Neuropathology and imaging
Thal, D. R. (2016) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2016.01.001 · Cited by 3
Editorial: Tau Pathology in Neurological Disorders
Carmo, S. D., Spillantini, M. G., & Cuello, A. C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.754669 · Cited by 3
Vandenberghe, M. E. (2015) · theses.fr (ABES) · doi:10.70675/c7b69fb2z393bz46fcz9000z5a9c52ba79c4 · Cited by 3
Research on the pathogenesis of Alzheimer's disease based on thalamocortical computational model
Gang, Y., Li, T., Xu, X., Zheng, Q., & Wang, W. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1353305 · Cited by 2
Yuasa, K., Hirosawa, T., Soma, D., Furutani, N., Kameya, M., Sano, M., Kitamura, K., Ueda, M., & Kikuchi, M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1272120 · Cited by 2
Depression in Alzheimer's disease : biomarkers and treatment
Enache, D. (2015) · Figshare · Cited by 2
Lindgrén, N. (2021) · UTUPub (University of Turku) · Cited by 2
Assessment of Alzheimer-related Pathologies of Dementia Using Machine Learning Feature SelectionPreprint
Rajab, M. A., Jammeh, E., Taketa, T., Brayne, C., Matthews, F. E., Su, L., Ince, P. G., Wharton, S. B., & Wang, D. Y. Q. (2022) · Research Square · doi:10.21203/rs.3.rs-1584607/v1 · Cited by 2
Gaetani, L., Nardi, G., & Parnetti, L. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2700246 · Cited by 1
Benefits in Disease Prevention, Control, and Cure
Sanders, C. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-56372-5_7 · Cited by 1
Huang, Y. H., Jia, H., & Bao, W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00013-6 · Cited by 1
Diagnosi clinicolaboratoristica della malattia di Alzheimer
Lagarde, J., Olivieri, P., Bottlaender, M., & Sarazin, M. (2021) · EMC - Neurologia · doi:10.1016/s1634-7072(21)45320-1 · Cited by 1
The manifold works of Prof. Michal Novak
Novák, P., & Žilka, N. (2021) · General Physiology and Biophysics · doi:10.4149/gpb_2021045 · Cited by 1
Neuroimaging Biomarkers in Alzheimer’s Disease and Related Disorders
Masdeu, J. C., & Pascual, B. (2023) · Springer eBooks · doi:10.1007/978-3-031-43356-6_11 · Cited by 1
Mattsson, P., Cselényi, Z., Morén, A. F., Freund‐Levi, Y., Wahlund, L., Halldin, C., & Farde, L. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231013 · Cited by 1
“Hippocampus remains mildly involved with relatively few A (cid:2) deposits while deposits continue to increase in isocortex [2, 30].”
BackgroundResultKent, B. A. (2015) · Apollo (University of Cambridge) · doi:10.17863/cam.16474 · Cited by 1
Villegas, B. J. (2017) · eScholarship (California Digital Library) · Cited by 1
Alfakir, R. (2021) · Research Square · doi:10.21203/rs.3.rs-384231/v2 · Cited by 1
“27 doi:10.1212/01.wnl.0000228230.26044.a4 28 Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., . . . Dickson, 29 D. W. (2015).”
Influential
Metadata
- Authors
- Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., Rawal, B., Parisi, J. E., Petersen, R. C., Kantarci, K., Ross, O. A., Duara, R., Knopman, D. S., Jack, C. R., & Dickson, D. W.
- Affiliations
- Mayo Clinic (US)
- University of Miami (US)
- Corresponding author
- Murray, Melissa E.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-03-23
- Volume
- 138
- Issue
- 5
- Pages
- 1370-1381
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC4407190
- OpenAlex
- W2148457471
- Cited by
- 324
- References
- 72
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 22 · 2023: 15 · 2022: 18 · 2021: 32 · 2020: 38 · 2019: 41 · 2018: 34 · 2017: 36 · 2016: 35 · 2015: 25
- FWCI
- 35.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- National Institute on Aging (R01AG040042, U01AG006786, R01AG011378, R01AG041851, P50AG016574)
- National Institute of Neurological Disorders and Stroke (P50NS072187)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, 11C-Pittsburgh compound B, amyloid PET, amyloid plaques, APOE ε4, cerebral amyloid angiopathy, thioflavin S staining, age of onset, disease duration, amyloid biomarkers
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Aniline Compounds, Female, Humans, Male, Middle Aged, Thiazoles, Amyloid beta-Peptides, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.